Back to Results

Armata Pharmaceuticals Inc (ARMP)

Featured in Overvalued Stocks

Armata Pharmaceuticals Inc is a common stock listing on the NYSE under the symbol ARMP. The company is a clinical-stage biotechnology business focused on developing targeted bacteriophage therapeutics for antibiotic-resistant infections. Its pipeline includes AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa, and AP-PA03 for pneumonia. Armata is also involved in a research collaboration with Merck Sharp & Dohme Corp. to develop synthetic bacteriophage candidates aimed at undisclosed infectious disease agents. The company is based in Los Angeles, California, and operates as a subsidiary of Innoviva, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-ARMP
$3.51
-31.4% Downside
Overvalued
$17.50
241.8% Upside
Bargain
Weak
—
—
—
0.0%
August 18, 2026
-0.6x
-0.6x
34.6x
185.8 M
548.8 M
66.8%
31.1%
-14.3
—
8.7%
Send a message
Valuation • Fair Value

Armata Pharmaceuticals Inc (NYSE-ARMP) Fair Value by Valuation Model

Compare the primary fair value estimate for Armata Pharmaceuticals Inc (NYSE-ARMP) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.51

Estimated downside of 31.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.51

Comparable-company valuation reference.

Analyst Price Target

$17.50

Analysts imply upside of 241.8%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Armata Pharmaceuticals Inc (NYSE-ARMP) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Armata Pharmaceuticals Inc (NYSE-ARMP)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

5.202 M

Current operating scale indicator.

Revenue Forecast

2.2 M

Forward revenue estimate.

EBITDA

-30.205 M

Current operating profitability reference.

EBITDA Forecast

-41.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Armata Pharmaceuticals Inc (NYSE-ARMP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Armata Pharmaceuticals Inc (NYSE-ARMP)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-14.3

Lower score that deserves closer risk review.

FCF / Net Income

8.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Armata Pharmaceuticals Inc (NYSE-ARMP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Armata Pharmaceuticals Inc (NYSE-ARMP)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 18, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Armata Pharmaceuticals Inc (NYSE-ARMP), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Armata Pharmaceuticals Inc (NYSE-ARMP) Stock Forecast & Technical Outlook

Review Armata Pharmaceuticals Inc (NYSE-ARMP) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Armata Pharmaceuticals Inc (NYSE-ARMP) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Armata Pharmaceuticals Inc (NYSE-ARMP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Armata Pharmaceuticals Inc (NYSE-ARMP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Armata Pharmaceuticals Inc (NYSE-ARMP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Armata Pharmaceuticals Inc (NYSE-ARMP) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Armata Pharmaceuticals Inc (NYSE-ARMP)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Armata Pharmaceuticals Inc (NYSE-ARMP) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Armata Pharmaceuticals Inc (NYSE-ARMP) Stock FAQ

Quick answers about Armata Pharmaceuticals Inc (NYSE-ARMP) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.51
Estimated downside 31.4%
Valuation Rating
Overvalued
Estimated downside of 31.4%
Analyst Target
$17.50
Implied upside 241.8%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Armata Pharmaceuticals Inc (NYSE-ARMP) is $3.51. This implies an estimated downside of 31.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 31.4% versus the current market price.

The available analyst price target for Armata Pharmaceuticals Inc (NYSE-ARMP) is $17.50. The analyst target implies estimated upside of 241.8%.

The current financial health read for Armata Pharmaceuticals Inc (NYSE-ARMP) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Armata Pharmaceuticals Inc (NYSE-ARMP) is August 18, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Armata Pharmaceuticals Inc (NYSE-ARMP) is -0.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Armata Pharmaceuticals Inc is 185.8 M.

The current enterprise value listed for Armata Pharmaceuticals Inc is 548.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Armata Pharmaceuticals Inc is NYSE-ARMP, and the stock is listed on NYSE.

Armata Pharmaceuticals Inc (NYSE-ARMP) is listed on NYSE.

The current debt-to-total-capital ratio listed for Armata Pharmaceuticals Inc is 66.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Armata Pharmaceuticals Inc is 31.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NYSE View more

AbbVie Inc (ABBV) AbbVie Inc (ABBV)
Arcus Biosciences Inc (RCUS) Arcus Biosciences Inc (RCUS)
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Evommune Inc (EVMN) Evommune Inc (EVMN)
Emergent Biosolutions Inc (EBS) Emergent Biosolutions Inc (EBS)
Perspective Therapeutics Inc (CATX) Perspective Therapeutics Inc (CATX)
Lineage Cell Therapeutics Inc (LCTX) Lineage Cell Therapeutics Inc (LCTX)
Protalix Biotherapeutics Inc (PLX) Protalix Biotherapeutics Inc (PLX)
Adc Therapeutics SA (ADCT) Adc Therapeutics SA (ADCT)
Pelthos Therapeutics Inc (PTHS) Pelthos Therapeutics Inc (PTHS)
Maia Biotechnology Inc (MAIA) Maia Biotechnology Inc (MAIA)
Annovis Bio Inc (ANVS) Annovis Bio Inc (ANVS)
OS Therapies Inc (OSTX) OS Therapies Inc (OSTX)
NanoViricides Inc (NNVC) NanoViricides Inc (NNVC)
Serina Therapeutics Inc (SER) Serina Therapeutics Inc (SER)
Apimeds Pharma US Ltd (APUS) Apimeds Pharma US Ltd (APUS)
Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM)
CEL-SCI Corp (CVM) CEL-SCI Corp (CVM)
Theriva Biologics Inc (TOVX) Theriva Biologics Inc (TOVX)
Regentis Biomaterials Ltd (RGNT) Regentis Biomaterials Ltd (RGNT)
Aeon Biopharma Inc (AEON) Aeon Biopharma Inc (AEON)
Can Fite Biopharma Ltd ADR (CANF) Can Fite Biopharma Ltd ADR (CANF)
Kairos Pharma Ltd (KAPA) Kairos Pharma Ltd (KAPA)
AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM)